Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial - Meyer, T; Fox, R; Ma, Y T (Lancet Gastroenterol Hepatol, 2017)
et al.